Back to search results

Suzetrigine for Pain After Total Hip Replacement

This study is looking at a new, non-opioid pain medication called Suzetrigine (Journavx™) for people having total hip replacement surgery. Many people need strong pain medicine after this surgery, and opioids can have side effects like nausea and constipation. Suzetrigine works by targeting specific pain receptors in your body, and it's already approved by the FDA for moderate to severe acute pain. Researchers want to see if Suzetrigine can help reduce the amount of opioid pain medicine you need in the first 48 hours after surgery. You might be able to join if you are between 18 and 80 years old, having your first total hip replacement, and meet other health criteria.

Study design
This study plans to enroll 210 participants. You would be randomly assigned to receive either Suzetrigine or a placebo (an inactive substance).
What's involved
You would receive Suzetrigine or placebo for seven days, with the first dose given before your surgery.
Compensation
Not stated in the trial record.
Follow-up
The main focus of the study is to measure opioid use within the first 48 hours after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07226700

Suzetrigine in Total Hip Arthroplasty

Recruiting
PHASE3Ages 18–80InterventionalTreatment
Hospital for Special Surgery, New York
~210 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:SuzetriginePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cumulative opioid consumption within the first 48 hours after THA starting from PACU entry (t=0), in oral morphine equivalents
Measured over From entry into the post-anesthesia care unit (PACU) to 48 hours after THA surgery

Conditions

Total Hip Arthroplasty (THA)
Total Hip Arthroplasty \(THA\)
Total Hip Replacement
Total Hip Replacement Surgery
Total Hip Replacements
Total Hip Replacement Arthroplasty
Suzetrigine
Pain Management
Pain
Nav 1.8
JOURNAVX
Opioid Cessation
Opioid Consumption, Postoperative
Multimodal Analgesia
Randomized Controlled Trial
Randomized Controlled Study
Randomized Controlled Trials

Explore related trials

Total replacement of hip

Where it's being run

1 sites across 1 states
New York1

Who to contact

Tina Chen
[email protected]
6467146509
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients undergoing primary THA (posterior approach) with participating surgeons
Age 18 to 80 years old
Planned discharge to home
Planned use of neuraxial anesthesia
American Society of Anesthesiologists (ASA) Physical Status 1 - 3

Exclusion

ASA greater than 3
Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)
History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)
History of QT prolongation
Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device
Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse
Inability to comply with any component of the study protocol
Younger than 18 or greater than 80 years old at the time of enrollment
Patient already on Suzetrigine
Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease/Child Pugh B or C, use of strong CYP3 inhibitors or inducers)
Contraindications to neuraxial anesthesia or any other part of the study protocol
Participation in another investigational drug or device study
Pregnancy

What this trial measures

  • Cumulative opioid consumption within the first 48 hours after THA starting from PACU entry (t=0), in oral morphine equivalentsFrom entry into the post-anesthesia care unit (PACU) to 48 hours after THA surgery

    The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU). This measure will be taken from EPIC via the MAR and documented in the study "MUD"; post-discharge, patient to report date/time of opioid use # of pills, dose in diary and documented in study "MUD". Measurements will be taken in PACU and 0-48 hrs following surgery.